MDA Seeks Information on Zolgensma Tumor Reports
The Muscular Dystrophy Association is reviewing safety data after Novartis reported tumor cases in patients treated with the spinal muscular atrophy gene therapy.
Updated on Nov. 6, 2026 in Cancer
Novartis has reported tumor cases in people treated with Zolgensma, a gene therapy for spinal muscular atrophy. The Muscular Dystrophy Association has contacted Novartis and is seeking more information about the reports.
Why it matters
Zolgensma is used to treat a serious genetic condition, so reports of tumors in treated patients raise questions for families weighing treatment options. Clear information on the nature and timing of these cases will be important for clinicians and patients across the United States.
The available reporting describes tumor cases from the manufacturer without specifying how many occurred or how they compare to other patients. Key details about timing, tumor type and monitoring remain unknown.
The players
Muscular Dystrophy Association
The Muscular Dystrophy Association is a nonprofit health organization that funds research and provides services for people with neuromuscular diseases, including spinal muscular atrophy.
Novartis
Novartis is a Swiss multinational pharmaceutical company that manufactures Zolgensma, a gene therapy for spinal muscular atrophy.
The details
Novartis reported the tumor cases in people treated with Zolgensma, a gene therapy used for spinal muscular atrophy. The Muscular Dystrophy Association is reviewing available safety and scientific data with clinical and research experts and urges families with immediate concerns to speak with their healthcare providers.
Timeline
Novartis's tumor reports and the Muscular Dystrophy Association's statement were published in early November 2026.
Health Landscape
The reports concern Zolgensma, a gene therapy approved for spinal muscular atrophy, and add to ongoing scrutiny of the safety profile of adeno-associated virus gene therapies. The findings will matter for how regulators and clinicians weigh long-term monitoring for these treatments.
Families with a child on or considering Zolgensma should speak with their healthcare providers about the reported tumor cases and any monitoring they may need. Treatment decisions should be made with a clinician who can review the individual's situation.
The takeaway
Patients and families should rely on their healthcare team for individualized guidance as more information about the Zolgensma tumor reports becomes available. Watching for updates from the manufacturer and patient organizations will help clarify what is known.
Further reading
Explore more on cancer developments and research.
